Qlaris Bio Taps Veteran Leader to Push a New Frontier in Glaucoma Care

DEDHAM, MA – July 29, 2026

In the world of clinical-stage biotechnology, board appointments are rarely just about filling a seat. They are strategic signals, chess moves that telegraph a company’s ambitions and readiness for its next critical phase. The recent announcement that Qlaris Bio has appointed Parisa Zamiri, M.D., Ph.D., to its board of directors is a textbook example. As the company shepherds its first-in-class glaucoma therapy, QLS-111, through the gauntlet of late-stage clinical trials, the addition of a seasoned ophthalmic drug developer is a clear statement of intent: Qlaris is gearing up for the final push.

This move goes far beyond a simple personnel update. It underscores a pivotal moment for a company aiming to disrupt a multi-billion-dollar market by treating glaucoma in a way no approved therapy has before. For investors, physicians, and the millions of patients living with this progressive disease, it’s a development that warrants a closer look beyond the headline.

A Strategic Play for a High-Stakes Field

To understand the significance of Dr. Zamiri’s appointment, one must appreciate the precarious journey from promising molecule to approved medicine. This path is littered with scientific and regulatory hurdles, and navigating it requires more than just innovative science; it demands deep, experience-based wisdom. Dr. Zamiri’s resume reads like a blueprint for exactly that.

A physician-scientist with credentials from the University of London, Moorfields Eye Hospital, and a Ph.D. in ocular immunology from a Harvard Medical School-affiliated institute, she embodies the crucial link between clinical reality and biopharmaceutical development. Her career includes high-impact leadership roles where she was directly responsible for steering novel therapies through the complex clinical and regulatory process.

At Novartis, she served as Vice President and Global Head of Clinical Development for Ophthalmology, overseeing trials from Phase 1 through post-market studies. More recently, as Chief Medical Officer at companies like Graybug Vision and Complement Therapeutics, she was instrumental in advancing therapies for other debilitating eye diseases like wet age-related macular degeneration (AMD) and geographic atrophy. Her work has consistently placed her at the forefront of ophthalmic innovation, guiding assets through the very stages Qlaris and QLS-111 are now entering.

“Dr. Zamiri brings a deep ophthalmic drug development expertise to the company,” said Ron Hunt, Chairman of the Board at Qlaris Bio, in a statement accompanying the announcement. “As we advance QLS-111 through late-stage development, her extensive experience translating novel mechanisms into approvable therapies will be a tremendous asset to our board.” This is the corporate translation of a simple truth: when you’re trying to launch a first-in-class drug, you bring in someone who knows the playbook by heart.

Redefining the Attack on Glaucoma

The strategic importance of this appointment is magnified by the science it is intended to support. Qlaris Bio isn’t developing a “me-too” drug. Its lead candidate, QLS-111, represents a fundamental shift in how glaucoma is treated.

For decades, the standard of care has focused on lowering intraocular pressure (IOP) by either reducing the production of aqueous humor—the fluid inside the eye—or by increasing its outflow through the eye’s primary drainage pathways. Think of it as turning down the faucet or clearing the main drain. While effective for many, these approaches have limitations. Side effects can hinder patient adherence, and for a significant subset of patients, including those with normal-tension glaucoma, IOP remains stubbornly high or disease progresses despite treatment.

QLS-111 targets a different part of the system entirely: the episcleral venous pressure (EVP). This is the pressure in the network of veins that drains fluid from the eye. It represents a floor below which IOP cannot drop, regardless of how well other drainage pathways are working. It’s a component of eye pressure that, until now, has been unaddressed by any approved therapy. QLS-111, a topical ATP-sensitive potassium channel modulator, works by dilating these vessels, lowering this downstream resistance and thereby reducing overall IOP.

“Qlaris is pursuing a truly differentiated approach to glaucoma by targeting episcleral venous pressure, a component of intraocular pressure that has gone unaddressed by currently approved treatments,” Dr. Zamiri noted. Her enthusiasm highlights the drug’s potential to carve out a unique and vital space in the treatment landscape. It could serve as a standalone therapy for those who don’t respond to current drugs or as a powerful complementary agent, providing an additional mechanism for IOP reduction.

Promising results from Phase 2 trials, named Osprey and Apteryx, have already demonstrated sustained IOP reduction with a favorable safety profile. Critically, Qlaris is also investigating QLS-111 in a Phase 2 trial for normal-tension glaucoma—a challenging form of the disease where optic nerve damage occurs despite normal eye pressure, and for which new options are desperately needed.

The Physician-Scientist in the Boardroom

Dr. Zamiri's career trajectory is emblematic of a powerful trend in the biotech industry: the rise of the physician-scientist as a key strategic leader. These individuals possess a rare dual fluency, speaking the languages of both the laboratory and the clinic. They understand the molecular mechanisms of a drug candidate but also the practical realities of patient care, treatment burdens, and the unmet needs that physicians face daily.

This perspective is invaluable for a company like Qlaris. A leader with clinical experience can help ensure that trial designs are not only scientifically rigorous but also practical and relevant to what will ultimately drive adoption by doctors and patients. They can anticipate regulatory questions, foresee market access challenges, and help shape a development strategy that is aimed squarely at demonstrating meaningful clinical value.

By adding Dr. Zamiri, Qlaris isn’t just gaining a drug developer; it's integrating the voice of the physician and the patient directly into its highest level of strategic oversight. This alignment is critical for avoiding the costly missteps that can occur when R&D becomes disconnected from real-world medicine. In an industry where the vast majority of drugs fail in development, this kind of integrated expertise can be a significant differentiating factor, de-risking the asset and increasing the probability of success.

As Qlaris Bio moves forward, the combination of its novel science and its newly fortified leadership will be a key narrative for the market to watch. The successful development of QLS-111 would not only represent a significant financial win for the company and its investors but would also deliver a long-awaited new tool for ophthalmologists and a new source of hope for millions of patients at risk of irreversible vision loss. The next stage of clinical development will be the ultimate test of this promising strategy.